Search Within

Rachel K Kim

Formats
  1. Journal Article (4)
  2. Meeting Abstract (3)
Groups
  1. Department of Medicine (7)
  2. Nursing (7)
  3. Solid Tumor Oncology Division (7)
  4. Thoracic Oncology (7)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (6)
  6. GSK Faculty (6)

More Groups

People
  1. Linda Ahn (7)
  2. Paul Paik (5)
  3. Andrew Plodkowski (4)
  4. Charles Rudin (4)
  5. Mark Kris (4)
  6. Ai Ni (3)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2020 (2)
  4. 2019 (2)
  5. 2018 (1)
Publications
  1. Journal of Clinical Oncology (2)
  2. Journal of Thoracic Oncology (2)
  3. Clinical Cancer Research (1)
  4. JAMA Oncology (1)
  5. Nature Communications (1)
Publishers
  1. American Society of Clinical Oncology (2)
  2. Elsevier Inc. (2)
  3. American Association for Cancer Research (1)
  4. American Medical Association (1)
  5. Nature Publishing Group (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228
    Journal Article

    Paik, P. K.; Fan, P. D.; Qeriqi, B.; Namakydoust, A.; Daly, B.; Ahn, L.; Kim, R.; Plodkowski, A.; Ni, A.; Chang, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas
    Journal Article

    Paik, P. K.; Luo, J.; Ai, N.; Kim, R.; Ahn, L.; Biswas, A.; Coker, C.; Ma, W.; Wong, P.; Buonocore, D. J.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: A phase 1/2 single-group open-label trial
    Journal Article

    Yu, H. A.; Schoenfeld, A. J.; Makhnin, A.; Kim, R.; Rizvi, H.; Tsui, D.; Falcon, C.; Houck-Loomis, B.; Meng, F.; Yang, J. L.; more...
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • A phase II trial of albumin-bound paclitaxel and gemcitabine in patients with newly diagnosed stage IV squamous cell lung cancers
    Journal Article

    Paik, P. K.; Kim, R. K.; Ahn, L.; Plodkowski, A. J.; Ni, A.; Donoghue, M. T. A.; Jonsson, P.; Villalona-Calero, M.; Ng, K.; McFarland, D.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers
    Meeting Abstract

    Yu, H. A.; Kim, R.; Makhnin, A.; Ahn, L. S. H.; Ni, A.; Hayes, S. A.; Young, R. J.; Riely, G. J.; Kris, M. G.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228
    Meeting Abstract

    Paik, P. K.; Ahn, L. S. H.; Ginsberg, M. S.; Plodkowski, A. J.; Kim, R.; Doyle, L. A.; Rudin, C. M.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A phase II trial of albumin-bound paclitaxel and gemcitabine in patients with newly diagnosed stage IV squamous cell lung cancers
    Meeting Abstract

    Paik, P.; Kim, R.; Ahn, L.; Plodkowski, A.; Ng, K.; McFarland, D.; Iqbal, A.; Eng, J.; Rudin, C.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save